Retatrutide GLP-1 / GIP / Glucagon Triple Agonist

Retatrutide is a synthetic peptide that activates three different metabolic receptors (specialised docking points on cells) at the same time: GLP-1, GIP, and glucagon receptors. Each of these is involved in how the body manages energy, responds to insulin (the hormone that controls blood sugar), and processes fat. By targeting all three at once, it gives researchers a tool for studying how these pathways work together.

Retatrutide is a synthetic peptide engineered to act as a triple agonist at three distinct G protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This multi-receptor profile is structurally and pharmacologically distinct from single-agonist (GLP-1R only, e.g. semaglutide) and dual-agonist (GLP-1R/GIPR, e.g. tirzepatide) compounds — the simultaneous activation of all three metabolic receptor pathways provides researchers with a tool for studying combined receptor interactions in metabolic signalling that cannot be replicated with simpler agonist compounds.

Preclinical research on triple GLP-1/GIP/glucagon agonists has examined their effects on energy expenditure, adipose tissue lipolysis, hepatic glucose output, and pancreatic beta cell function. The GLP-1R component is associated with insulin secretion and gastric motility research; the GIPR component with insulin potentiation and lipid metabolism studies; and the glucagon receptor component with energy expenditure and hepatic glycogenolysis. Studies have examined how simultaneous agonism across all three receptors produces additive or synergistic effects on metabolic markers in rodent models, including adiposity, glucose tolerance, and lipid panels.

As the most pharmacologically complex compound in the Velox Peptides catalogue, Retatrutide is primarily of interest to researchers studying multi-receptor metabolic signalling, incretin biology, and energy homeostasis. Its availability in multiple vial sizes (10mg, 15mg, 20mg) and a 10mg 10-pack supports both cell culture and more extensive preclinical study designs. Velox Peptides supplies Retatrutide at ≥99% HPLC-verified purity as a lyophilised research reagent with batch certificate of analysis. Not for human or veterinary consumption.

Summary paraphrased from the peer-reviewed preclinical literature. For in vitro research use only. For source citations, email support@veloxpeps.com.

This Retatrutide was analysed by Janoshik Analytical, the peptide industry's reference third-party lab, as an anonymous blind test — the lab was not told whose product it was, so the result carries no supplier bias. The full report is hosted on Janoshik's own servers and you can verify it directly below.

Janoshik Task #165920 · GLP-1 blind panel (semaglutide / tirzepatide / retatrutide) · analysis conducted 30 June 2026.

Every order also ships with its own batch-specific Certificate of Analysis. Previous batch CoAs are archived in the CoA library. For a batch-specific CoA prior to purchase, contact support@veloxpeps.com.

Retatrutide is sold by Velox Peptides (CRP Labs Ltd, UK company no. NI738125) and dispatched from the UK. Choose a vial size, pay on one page, and your order is dispatched the next working day.

• Delivery: Royal Mail Tracked 24 (1–2 working days, £5.99, free over £100) or Tracked 48 (2–3 working days, £3.80). See shipping.
• Payment: Pay by Bank through FCA-authorised open banking, or bank transfer. No card details needed.
• Testing: See the batch testing details above and past reports in the CoA library.
• Research use only: Supplied as a research reagent for in vitro use. Not for human or veterinary consumption. See our Research Use Policy.